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KESAN EKSTRAK Sandoricum koetjape (buah sentul) KE ATAS AKTIVITI 
HIPOKOLESTEROLEMIK MELALUI UJIAN 3-HIDROKSIL-3-
METILGLUTARIL-COENZIM A REDUKTASE (HMGR) 
ABSTRAK 
Sandoricum koetjape, sejenis pokok buah-buahan tropika yang kaya dengan 
pitokimia terpenoids, telah dihipotesiskan untuk merencat sintesis kolesterol melalui 
perencatan ke atas aktiviti HMG-Coa reduktase (HMGR). HMGR, sejenis enzim 
sintesis kolesterol penghad-kadar yang mengandungi dua domain, iaitu domain 
sterol-sensing N-terminal (residu 1-339) dan domain katalitik C-terminal (residu 
460-888). Kajian ini telah dirangka untuk mengkaji aktiviti hipokolesterolemik bagi 
ekstrak S. koetjape melalui perencatan ke atas rekombinan enzim HMGR manusia. 
Menerusi kajian yang dijalankan, serpihan gen yang mengkodkan domain katalitik 
HMGR telah diekspress dan ditulenkan sebagai protein penanda rekombinan 
glutathione S-transferase. Penulenan bagi subunit katalitik telah dilakukan 
menggunakan kolum afiniti GSTrapFF. Ujian enzim secara in vitro menunjukkan 
bahawa aktiviti katalitik adalah berdasarkan kepada pengukuran kinetik. Empat 
bahagian pada S. koetjape iaitu daun, batang, kulit dan isi buah telah diproses untuk 
menghasilkan ekstrak kasar metanol. Batang pokok telah dikenalpasti sebagai 
perencat yang paling berpotensi dengan IC50 < 5 µg/ml, diikuti oleh kulit buah (IC50 
= 32.5 µg/ml), daun (IC50= 37.6 µg/ml) dan isi buah (IC50 = 68.3 µg/ml). 
Kesimpulannya, keempat-empat bahagian S. koetjape telah menunjukkan kesan 
aktiviti hipokolestrolemia melalui perencatan HMGR. Hasil penemuan ini 
membuktikan bahawa S. koetjape berpotensi untuk kajian lanjutan sebagai agen 
hipokolestrolemia. 
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EFFECT OF Sandoricum koetjape (buah sentul) EXTRACTS ON 
HYPOCHOLESTEROLEMIC ACTIVITY USING 3-HYDROXY-3-
METHYLGLUTARYL-COENZYME A REDUCTASE (HMGR) ASSAY 
ABSTRACT 
 Sandoricum koetjape, a tropical fruit tree rich in phytochemical terpenoids, 
was postulated to suppress cholesterol synthesis through inhibition of HMG-CoA 
reductase (HMGR) activity. HMGR, a rate-limiting enzyme of cholesterol synthesis 
consists of two domains, N-terminal sterol-sensing domain (residues 1-339) and C-
terminal catalytic domain (residues 460-888). This research was designed to study 
the hypocholesterolemic activity of S. koetjape extract through inhibition of 
recombinant human HMGR. In this study, the gene fragment encoding the catalytic 
domain of HMGR was expressed and purified as a recombinant glutathione S-
transferase tagged protein. In vitro enzymatic assay revealed catalytic activity based 
on the kinetic measurements. Methanolic crude extracts of leaves, bark, fruit hull and 
flesh from S. koetjape exhibit in vitro inhibition activity significantly on the 
recombinant human HMGR. Bark was found to be the most potent inhibitor with 
IC50 <5 µg/ml, followed by fruit hull (IC50 = 32.5 µg/ml), leaves (IC50 = 37.6 µg/ml) 
and flesh (IC50 = 68.3 µg/ml). In summary, all four plant parts of S. koetjape 
exhibited hypocholesterolemic activity through HMGR inhibition. The promising 
finding revealed that S. koetjape is a good candidate for further research as a 
hypocholesterolemic agent.   
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CHAPTER 1 
INTRODUCTION 
1.1 Cardiovascular disease  
 Despite the tremendous advances in modern medicines, cardiovascular 
disease (CVD) remains the number one killer globally, making it the major concern 
in healthcare arena. In 2001, nearly one-third of global deaths were attributable to 
CVD where low- and middle-income countries contributed to 85% of all the CVD 
deaths (AHA, 2004). The number of deaths attributable to CVD continues to increase, 
and prevalence is increasing sharply in developing countries (Roger et al., 2011). 
According to the World Health Statistics 2011, the relative uncertainty range for 
deaths from CVD is ± 12% for high-income countries and ± 25-35% for sub-Saharan 
Africa (WHO, 2011). CVD is greatly associated with atherosclerosis, a medical 
condition where atherosclerotic plaque built up slowly in the arteries and remained 
asymptomatic until the arteries become severely narrowed or completely blocked 
(Roger et al., 2011). Atherosclerosis is the primary cause of cardiovascular incidents 
consists of stroke and heart attack. In fact, atherosclerosis is depicted by World 
Health Organization as the fundamental cause of cerebrovascular disease and 
coronary artery disease, the most common causes of morbid-mortality globally 
(Rader and Daugherty, 2008). 
 
1.2 Atherosclerosis 
 Atherosclerosis came from Greek words athero (meaning lump of paste) and 
sclerosis (hardening), which means the nodular accumulation of a soft, flaky, 
yellowish materials at the centre of arteries. The atherosclerotic plaque consists of 
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the deposit of cholesterol and other lipids, calcium, and large number of 
inflammatory cells including foam cells, T lymphocytes, B lymphocytes, dendritic 
cells and macrophages as shown in Figure 1.1 (Galkina and Ley, 2009).  
 
Figure 1.1: Immune cells involved in atherosclerosis (Adapted from Galkina, E. 
and Ley, K. 2009. Immune and inflammatory mechanisms of atherosclerosis. Annu 
Rev Immunol, 27, 165-197, Figure 1, page 33)  
 
 Two types of plaque are formed in the arterial walls, stable plaque and 
unstable plaque. The unique feature of stable plaque is a thick fibrous cap which 
comprised of smooth muscle cells. As the plaque grows, it narrows the lumen of the 
artery. Consequently, the supply of oxygen-rich blood to the heart, brain, and other 
body parts is restricted. Atherosclerosis leads to severe problems when this type of 
plaques causes a partial or complete obstruction of blood flow to heart and brain. The 
second type of plaque is unstable plaque, which is more dangerous because it has a 
thin cap comprised of macrophages, foam cells and less smooth muscle cells. As a 
result, it is more prone to plaque rupture and cause thrombus (blood clot) formation. 
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This sudden occlusion of the artery often leads to an acute, life-threatening heart 
attack. 
 Either type of plaques can lead to peripheral arterial disease, stroke, coronary 
artery disease and transient ischemic attack (Roger et al., 2011). Peripheral arterial 
disease happens when blood flow to the arms or legs is limited. The symptoms of 
peripheral arterial disease are pain and numbness. If left untreated, it can result in 
tissue death and gangrene (AHA, 2004).  Restriction of blood flow to parts of the 
heart can cause myocardial infarction (heart attack), angina (chest pain), weakened 
cardiomyocytes (heart muscles) or heart failure (Roger et al., 2011). Stroke and 
transient ischemic attack occurs when blood supply is blocked to parts of the brain. 
Transient ischemic attack often has similar symptoms as stroke; the symptoms 
normally pass within 1 hour up to 24 hours. It serves as a warning to future attacks 
and stroke. It can be seen that the consequences of atherosclerosis is deleterious and 
detrimental. Therefore, it is necessary to understand the different stages of 
atherosclerosis and its pathological determinant. 
 
1.2.1 Pathological events that lead to atherosclerosis 
 Atherosclerosis is a systemic coronary artery disease (CAD) with 
complicated pathogenesis involving a couple of highly interrelated processes, 
including oxidative stress, lipid disturbances, endothelial dysfunction, chronic 
inflammation, smooth muscle cell activation, altered matrix metabolism, platelet 
activation and thrombosis (Gerdes and Zirlik, 2011). Atherosclerosis arises at sites in 
the arterial tree where laminar flow is disrupted. It all begins with a fatty streak and 
develop into an intermediate lesion, subsequently into a lesion that is susceptible to 
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rupture. The progression of atherosclerosis may develop into an advanced obstructive 
lesion. Compelling evidences have indicated the role of inflammation in mediating 
all stages of atherosclerosis from initiation through progression (early asymptomatic 
vascular injury) and, ultimately the thrombotic complications (clinically manifest 
dysfunction).  
 Inflammatory signalling alters the behaviour of the vascular elements and 
intrinsic cells of the artery wall (endothelium and smooth muscle), further recruits 
immune cells that interact to promote lesion formation and complications, as shown 
in Figure 1.2 (Badimon et al., 2009). Early injury is characterized by endothelial 
expression of adhesion molecules, monocyte adhesion and transmigration into the 
subendothelial layer, differentiate into macrophages and subsequent transformation 
into foam cells (Puntmann et al., 2010). Parallel upregulation of hemostatic proteins 
induces a highly procoagulative state, in which platelets releasing their contents at 
the site of activated endothelium. The arterial wall remodels in response to 
continuous accumulation of plaque material. Initial preservation of arterial lumen 
cross-sectional area through means of circumferential expansion of the wall 
segments allows certain level of plaque burden before significant luminal narrowing, 
blood flow restriction, and CVD symptoms occur (Puntmann et al., 2010). Ongoing 
release of proinflammatory cytokines, activation of matrix metalloproteinases 
(MMPs), and neovascularization may cause plaque instability (Puntmann et al., 
2010).  
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Figure 1.2: Schematic representation of the progression of atherosclerotic 
plaque from initial stage of endothelial dysfunction to advanced stage with the 
presence of complicated plaques. (Adapted from Badimon, L., Vilahur, G. and 
Padro, T. 2009. Lipoproteins, platelet and atherothrombosis. Rev Esp Cardiol, 62(10), 
1161-78, Figure 3, page 1163) 
 
1.2.1.1 Initiation of atherosclerosis 
 Cholesterol is insoluble organic molecules which has very low solubility in 
aqueous media attributable to their highly hydrophobic characteristic. Lipoproteins 
are carriers composed of proteins and phospholipids that facilitate the transport of 
cholesterol in bloodstream (Badimon et al., 2009). Low-density lipoproteins (LDL) 
is the main cholesterol carrier that serves as an exogenous source of cholesterol and 
other cellular nutrients for hepatic and extrahepatic tissues, where it is taken up by 
receptor-mediated endocytosis (Osterud and Bjorklid, 2003).  
 Under physiological conditions, a multifactorial organ vascular endothelium 
plays an imperative role to recognize both systemic and local stimuli and thereby 
modify its functional status which contributes to the homeostasis of the vascular wall. 
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Endothelium is naturally equipped with a surface that prevents thrombosis (Badimon 
et al., 2009). It permits the exchange of numerous substances between the blood and 
tissues and controls the vascular tone and trafficking of inflammatory cells towards 
the vascular bed.  
 In regions of vascular bed predisposed to atherosclerotic lesions due to 
increased permeability, hypercholesterolemia may cause the increased of LDL 
transcytosis through vascular endothelium (Badimon et al., 2009). The presence of 
native or atherogenic LDL particles in the arterial intima led to a decrease in the 
bioavailability of endothelial nitric oxide (NO). The decreased in NO availability is 
associated with a reduction in the concentration and activation of nitric oxide 
synthetase (Badimon et al., 2009). Parallel changes in endothelial permeability 
further augment the inflammatory response by promoting the entry and retention of 
cholesterol-containing LDL particles in arterial intima (Libby et al., 2011). LDL 
retention in the arterial intima is a key process in the progression of atherosclerotic 
lesion. 
 LDL are subjected to a milieu conducive to various kinds of enzymatic and 
chemical modifications (Fan and Watanabe, 2003). Modification of LDL via 
oxidative processes is believed to be a prerequisite for the development of 
atherosclerosis. Basically, LDLs are modified by oxygen radicals (lipoxygenase, 
myeloperoxidase, sphingomyelinase and secretary phospholipase A2) (Rader and 
Daugherty, 2008). Oxidation of the particle in the arterial wall is thought to be a 
complex reaction involving several cell types such as endothelial cells, smooth 
muscle cells, granulocytes, macrophages, monocytes and lymphocytes (Osterud and 
Bjorklid, 2003). 
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 On the other hand, LDL may also undergo modification processes when they 
interact with extracellular matrix components such as proteoglycans, collagen, elastin, 
hydrolytic enzymes (esterase), proteolytic enzymes (metalloproteinases, tryptase, 
kinase, and thrombin), lipolytic enzymes (phospholipase A2, phospholipase C and 
sphingomyelinase) (Badimon et al., 2009). Collagen is vital for maintaining the 
integrity and elasticity of the vascular wall. However, it is a double-edge sword 
which also implicated in cell differentiation processes. The glycosylated forms of 
collagen are chief factor in atherogenesis as they favour LDL retention. In the 
nutshell, there are various chemical and structural processes that take place to 
generate different types of modified LDL particles.  
 Arterial endothelial cells, which normally resist attachment of the white blood 
cells streaming past them, express adhesion molecules that capture leukocytes on 
their surfaces when subjected to irritative stimuli such as dyslipidemia, hypertension 
or pro-inflammatory mediators (Libby et al., 2011). Inflammation results in the 
generation of chemokines such as CX3, CL1 and MCP-1, which in turn signal the 
adhesion and transmigration of monocytes into the arterial intima (Rader and 
Daugherty, 2008; Libby et al., 2002). Once resident in the artery wall, monocytes 
may differentiate into macrophages under the action of M-CSF, as shown in Figure 
1.2 (Fan and Watanabe, 2003). Macrophages secrete various factors involved in 
propagating the atherosclerotic plaque, including factors involved in proteolysis, 
inflammation and lipid metabolism (Rader and Daugherty, 2008).  
 
8 
 
1.2.1.2 Progression of atherosclerosis 
 A key feature in the development of atherosclerotic lesions is the infiltration 
of circulating monocytes into the subendothelial space. Under the condition of 
normal blood flow, selectin-mediated interactions are not sufficient to arrest rolling 
leukocytes. However, endothelial cells are susceptible and sensitive to the shear 
stresses provided by blood flow, which can change their morphology and trigger 
many signalling cascade, resulting LDL accumulation at sites of arterial branching or 
curvature, where flow is disturbed (Mestas and Ley, 2008). 
 The first step of atherosclerotic lesion development is leukocyte recruitment 
to the arterial wall. Leukocyte homing in this event proceeds through a well-defined 
dynamic adhesion cascade, including tethering, rolling, slow rolling, firm adhesion, 
and transmigration (Huo and Xia, 2009). Capture or tethering is the first step of 
leukocyte adhesion, which functions to decelerate fast-flowing leukocytes from the 
central blood stream and enables them to interact closely with the activated 
endothelium (Huo and Xia, 2009). Rolling leukocytes transduce signals from 
adhesion receptors, which activate downstream adhesion molecules that mediate 
slow rolling and firm adhesion to the endothelium, permitting the adherent 
leukocytes to infiltrate into the arterial wall (McNeill et al., 2010). Each of these 
steps is mediated by the coordinated actions of different adhesion molecules and 
chemokines.  
 It was found that the interactions of leukocyte integrins with members of the 
immunoglobulin family mediate firm adhesion and migration (Huo and Xia, 2009). 
Integrins are heterodimeric cell surface receptors that support both rolling and 
adhesion of leukocytes (Mestas and Ley, 2008). Upon activation, integrins undergo a 
series of conformational changes that result in increased binding affinity to their 
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respective ligands (Mestas and Ley, 2008). VLA-4 and the β2 integrin LFA-1 
constitutively, express E-selectin, L-selectin and P-selectin ligands (Figure 1.3) 
(Mestas and Ley, 2008). These selectins and their ligand (PSGL-1) also mediate the 
initial tethering and rolling events of leukocyte on the endothelium. Interactions 
between selectins and PSGL-1 serve as a braking system to decelerate fast-flowing 
leukocytes from the central blood stream, enabling them to adhere to and 
transmigrate underneath the activated endothelium (Huo and Xia, 2009; Mestas and 
Ley, 2008; McNeill et al., 2010).  
 Chemokines and chemokine receptors also play an imperative role in 
leukocyte adhesion and migration (Huo and Xia, 2009). For instance, MCP-1 plays a 
key role by means of the CCR2 receptors (Huo and Xia, 2009). Integrin activation is 
typically mediated by signals induced by chemokine receptor engagement that 
triggers arrest and firm adhesion (Mestas and Ley, 2008). Some chemokines can bind 
to the surface of endothelial cells, immobilize, and mediate arrest of rolling 
leukocytes. These chemokines can also bind to heparin sulphate, a glycoaminoglycan 
present on the surface of endothelial cells (Mestas and Ley, 2008). The association of 
chemokines with heparin sulphate immobilizes chemokines on the vessel wall, 
providing strong and localized signals for integrin activation (Mestas and Ley, 2008). 
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Figure 1.3: PSGL-1 mediated selective homing of monocytes.  This picture gives 
a closer view to the process of monocyte tethering and rolling on the endothelium 
through classic adhesion cascade, involving adhesion molecules and their ligands. 
(Adapted from Huo, Y. and Xia, L. 2009. P-selectin glycoprotein ligand-1 plays a 
crucial role in the selective recruitment of leukocytes into the atherosclerotic arterial 
wall. Trends Cardiovasc Med, 19(4), 140-5, Figure 2, page 143) 
   
 Macrophages are the predominant cellular components in atherosclerotic 
lesions. Macrophages found in lesions are differentiated from circulating blood 
monocytes, and these macrophages behave very differently (Huo and Xia, 2009). In 
the nascent atheroma, macrophages may take up deposited atherogenic LDL through 
scavenger receptors, engulf the lipoprotein particles and transformed into foam cells 
(lipid-laden macrophages) (Fan and Watanabe, 2003; Libby et al., 2002; Rader and 
Daugherty, 2008; Libby et al., 2011). M-CSF contributes to the differentiation of the 
blood monocyte into macrophage foam cell (Libby et al., 2002). The accumulation of 
foam cells in the atherosclerotic plaque leads to the formation of fatty streaks (Rader 
and Daugherty, 2008). 
 Atheroma formation also involves the recruitment of SMCs in the tunica 
media into the tunica intima (Libby et al., 2011). SMCs undergo phenotypic changes 
from differentiation to the acquisition of a synthetic phenotype under the effects of 
atherogenic stimuli (Badimon et al., 2009). Thus, SMCs with a nonproliferative 
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contractile phenotype, typically in healthy arteries, transform into actively 
proliferative cells (Badimon et al., 2009). During atherogenesis, SMCs migrate from 
the media into the intima when they are attracted by chemotactic agents, and 
proliferate within the intima in response to mediators like PDGF (Figure 1.2) (Libby 
et al., 2011). Vascular SMCs contributes to development of atherosclerotic lesion by 
secreting large amounts of extracellular-matrix molecules, including interstitial 
collagen and elastin, and form a fibrous cap that covers the plaque (Rader and 
Daugherty, 2008; Libby et al., 2011; Badimon et al., 2009). The presence of 
extracellular matrix increases the retention and aggregation of atherogenic 
lipoproteins (Rader and Daugherty, 2008).  
 Close interactions among infiltrated macrophages, foam cells, T lymphocytes 
and smooth muscle cells together with diverse cytokines and other biological effects 
decide the fate of the progression of atherosclerotic lesions (Fan and Watanabe, 
2003).  
 
1.2.1.3 Plaque rupture and thrombosis 
 Composition and stability of the plaque is an important determinant of 
atherosclerosis complications as plaques with high lipid content and excess 
macrophages in the cap is more susceptible to rupture (Rader and Daugherty, 2008). 
As the plaque grows, compensatory remodelling takes place, the size of the lumen is 
preserved while its overall diameter increases (Rader and Daugherty, 2008). 
Paradoxically, thrombotic complications do not always occur at the sites of the most 
severe arterial narrowing by plaques. Instead, thrombi often arise after fracture of the 
fibrous cap or erosion of endothelium, resulting in the exposure of plasma 
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thrombogenic materials including tissue factor, triggering thrombosis (Libby et al., 
2011).   
 In atherosclerotic plaque, macrophages degrade extracellular matrix by 
phagocytosis or by secreting proteolytic enzymes, in particular MMP9. MMP9 is a 
proteolytic enzyme of different extracellular matrix related proteins such as type IV 
collagen, laminin, and elastin, which may weaken the fibrous cap, predisposing its 
rupture (Badimon et al., 2009). In addition to macrophages, SMCs also release 
MMPs; further augment the progression and rupture of atherosclerotic plaques. 
Therefore, regulation of MMPs is crucial to reduce cardiovascular complications due 
to its inextricable role in the degradation of extracellular matrix in both physiological 
and pathological processes of plaque rupture (Bellosta et al., 1998). Emphasis also 
placed on another class of proteases, cathepsins, which have also been suggested to 
contribute to lesion disruption (Rader and Daugherty, 2008).  
 Plaque rupture with superimposed thrombosis is the major cause for acute 
coronary syndrome of unstable angina, heart attack, and sudden death (Rader and 
Daugherty, 2008). The underlying causes of these cardiac events are artery occlusion 
by large thrombus or relentless lesion growth. Large thrombus formation during 
plaque rupture can block artery and accountable for acute coronary syndrome or 
heart attack. If the plaque does not rupture and the lesion continues to grow, the 
lesion can encroach on the lumen and result in clinically obstructive disease (Rader 
and Daugherty, 2008). 
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1.2.2 Therapeutic options and clinical perspectives in the management of 
atherosclerosis 
 The therapeutic options proven to be promising in the management of 
atherosclerosis are limited to HDL modulators, anti-restenotic agents, anti-coagulant 
agents and HMG-CoA reductase (HMGR) inhibitors (Charo and Taub, 2011). Other 
therapies such as LDL modulators, anti-inflammatory agents, anti-oxidative agents 
and therapeutic cure targeting at angiogenesis are still under clinical trials 
investigation to prove their efficacy (Charo and Taub, 2011).  
 One of the established therapeutic targets in atherosclerosis is HMGR. 
HMGR inhibitor, generally referred to as statins is the leading therapeutic regimen 
for treating hypercholesterolemia (Greenwood et al., 2006). Currently, statins has 
become so prevalent in clinical use that they are now prescribed to more than 25 
million people worldwide, with the number expected to rise rapidly. Statins intercede 
biological effect through HMGR inhibition, an upstream rate-limiting enzyme in the 
cholesterol synthesis pathway (Greenwood et al., 2006). 
 Although statins were developed to specifically reduce cholesterol synthesis, 
clinical trials have indicated their beneficial effects extend beyond lipid lowering 
efficacy (Charo and Taub, 2011). The anti-inflammatory actions of statins described 
by previous evidences are decreased in expression of VCAM-1 by endothelial cell, 
attenuation of the growth of macrophages and their MMPs activity, and inhibition of 
interferon-γ production (Charo and Taub, 2011). The aforementioned activities had 
contributed to decrease in monocyte recruitment, T cell activation and thereby 
improve plaque stability (Charo and Taub, 2011).  
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 Owing to the tremendous benefits attributed by HMGR inhibitors and their 
clinically proven effectiveness in lowering cholesterol levels and reducing 
cardiovascular incidence, HMGR has been targeted for research. This research study 
has been initiated to search novel molecules that can reduce cholesterol level through 
HMGR inhibition.  
 
1.3 HMG-CoA reductase (HMGR) 
 HMG-CoA reductase (protein accession number: P04035) is involved in the 
conversion of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) into 
mevalonate, which is the precursor of cholesterol and other isoprenoids (Carbonell 
and Freire, 2005).  
 
1.3.1 Structure and binding properties 
 Human HMGR consists of a single polypeptide chain of 888 amino acids. 
The amino-terminal 1-339 residues are membrane bound and reside in the 
endoplasmic reticulum membrane, while soluble C-terminal portion (residues 460-
888), the catalytic domain of HMGR resides in its cytoplasm (Istvan and Deisenhofer, 
2000). A linker region (residues 340-459) connects the two portions of the protein 
(Istvan and Deisenhofer, 2000).  
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1.3.1.1 The architecture of HMGR 
 HMGR is anchored to membranes of the ER through its hydrophobic NH2-
terminal domain, which consists of eight membrane-spanning regions separated by 
short loops, as shown in Figure 1.4 (Roitelman et al., 1992). The membrane domain 
of HMGR precedes a large COOH-terminal domain that projects into the cytosol and 
exerts all of the catalytic activity of the enzyme (Gil et al., 1985; Liscum et al., 1985). 
 
Figure 1.4: Schematic diagram of HMGR. (Adapted from Debose-Boyd, R. A. 
2008. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination 
and degradation of HMG CoA reductase. Cell Res, 18(6), 609-21, Figure 2) 
 
 In year 2000, the structure of the catalytic domain of human HMGR (residues 
460-888) has been published and discussed (Protein Database codes: 1DQ8, 1DQ9, 
1DQA). The HMGR monomer reveals a unique structure comprised of three 
domains (Figure 1.5): an N-terminal helical domain, N-domain (residues 460-527), a 
large domain, L-domain (residues 528-590 and 694-872) and a small domain, S-
domain (residues 592-682) (Istvan et al., 2000). Substrate HMG-CoA binds to the L-
domain, while NADP(H), its co-substrate binds predominantly to the S-domain.  
Linker region 
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Figure 1.5: Ribbon diagram of the human HMGR monomer. The monomer 
consists of three domains: (1) the small, helical amino-terminal N-domain (green), (2) 
the large, central L-domain which contains the dimerization motif ENVIG (red), and 
(3) the small, ferredoxin-like S-domain which is inserted into the L-domain (blue). 
(Adapted from Istvan, E. S. and Deisenhofer, J. 2000. The structure of the catalytic 
portion of human HMG-CoA reductase. Biochimica et Biophysica Acta, 1529, 9-18, 
Figure 3, page 11) 
 
 
 The enzyme forms tetramers, shown in Figure 1.6. Four monomers of the 
catalytic portions of human HMGR are arranged in two dimers and combine to form 
a tetramer. The observation of large contact areas and residues at the interfaces 
which are typical for protein-protein interactions suggest the tetrameric structure of 
the catalytic portion of human HMGR in solution (Istvan et al., 2000). This is 
supported by results of analytical sedimentation and velocity ultracentrifugation 
experiments (Istvan et al., 2000).  
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Figure 1.6: Ribbon diagram of the human HMGR tetramer. The four different 
subunits are colored in yellow, blue, green, and purple. The N- and C-terminal of the 
four monomers are indicated. Each monomer contains one HMG-CoA molecule and 
one NADP molecule. (A) Front view of the human HMGR tetramer. (B) Side view 
of the human HMGR tetramer. (Adapted from Istvan, E. S. and Deisenhofer, J. 2000. 
The structure of the catalytic portion of human HMG-CoA reductase. Biochimica et 
Biophysica Acta, 1529, 9-18, Figure 2, page 10) 
. 
 
1.3.1.2 Sterol-sensing domain 
 The membrane-bound domains of mammalian HMGRs contain a 167 residue 
segment, termed as sterol sensing domain, shares approximately 25% sequence 
identity with membrane regions of other proteins that are also influenced by 
cholesterol (Istvan and Deisenhofer, 2000). This domain is responsible for the 
enhanced degradation of HMGR in response to increased concentrations of 
oxysterols (Istvan and Deisenhofer, 2000). The degradation of HMGR appears to be 
initiated when a membrane-bound cysteine protease cleaves within the 8 
transmembrane-span region of HMGR (Istvan and Deisenhofer, 2000; Moriyama et 
al., 1998). 
 ER protein insig-1 appears to play an essential role in the sterol-mediated 
degradation of HMGR (Sever et al., 2003). Part of the underlying mechanism is 
associated with sterol-activated binding of the sterol-sensing domain of HMGR to 
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insig-1 as determined by coimmunoprecipitation (Sever et al., 2003). The N-terminal 
of sterol-sensing domain, which is the most conserved region mediates accelerate 
degradation of HMGR in the presence of sterols (Luskey and Stevens, 1985). This 
sterol-regulated degradation is an important mechanism for feedback suppression of 
HMGR activity and regulation of cholesterol metabolism in humans, one of several 
strategies animal cells use to limit production of cholesterol (Luskey and Stevens, 
1985; Sever et al., 2003; Song et al., 2005). 
 The sterol-accelerated degradation of HMGR is depicted in Figure 1.7. After 
binding to insig-1, HMGR is degraded within the ER, by a process mediated by 
ubiquitination and proteasomal degradation (Sever et al., 2003). Figure 1.7 shows 
that gp78, a membrane bound E3, is an insig-1-associated protein. It was found that 
insig-1 binds to the membrane domain of gp78 in the absence and presence of sterols.  
Upon the addition of sterols, HMGR is recruited to the complex (Song et al., 2005). 
Binding of HMGR to insig-1, along with its associated proteins gp78 and VCP, 
triggers the polyubiquitination of HMGR in a reaction mediated by gp78 and its 
cognate E2 (Song et al., 2005). Gp78 is the ubiquitin ligase that initiates sterol-
dependent degradation of HMGR, and insig-1 is the bridge between gp78 / VCP and 
the HMGR (Song et al., 2005). Ubiquitination of an enzyme is an oblidate reaction 
of recognition and degradation of enzyme and VCP is an ATPase that participates in 
post-ubiquitination steps of ER-accelerated degradation (Song et al., 2005). In other 
words, VCP is required for HMGR degradation. Ubiquitination of HMGR marks the 
enzyme for recognition by VCP and its cofactors, which act to extract ubiquitinated 
HMGR molecules from the ER membrane and present them to cytosolic 26S 
proteasomes for degradation, as shown in Figure 1.7 (Song et al., 2005).  
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  In conclusion, the increase in the rate of HMGR degradation occurs when 
sterol concentrations are high. Sterol-mediated degradation does not influence the 
degradation of the catalytic portion in cytoplasmic region but the sterol-sensing 
domain resides in the transmembrane region. 
 
Figure 1.7: Schematic representation for the pathway of sterol-accelerated 
degradation of HMGR. (Adapted from Song, B. L., Sever, N. and Debose-Boyd, R. 
A. 2005. Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and 
couples sterol-regulated ubiquitination to degradation of HMG-CoA reductase. 
Molecular Cell, 19, 829-840. Figure 6, page 837) 
 
1.3.1.3 Substrate binding and catalysis 
 The extended substrates HMG-CoA and NADPH molecules make numerous 
contacts with L- and S-domains of the protein to form the four active sites in the 
tetramer (Istvan et al., 2000). At each active site, the HMG moiety of one HMG-CoA 
molecule, which is predominantly bound to a single monomer, comes into proximity 
of the nicotinamide ring of an NADP(H) molecule, whose binding pocket is located 
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in the neighboring monomer (Istvan et al., 2000). Thus, the active site is located at 
the interface of the two monomers of a dimer. The binding of NADP(H) causes a 
conformational change in the C-terminus of the enzyme that results in the ordering of 
helix Lα11 and the complete closure of the active site. (Istvan and Deisenhofer, 2000) 
 
(a.) Coenzyme A binding 
Coenzyme A binds in an extended conformation: the ADP moiety of CoA is located 
in a positively charged pocket near the enzyme surface. Multiple interactions 
between HMGR and CoA are formed by the L-domain of one monomer (Figure 1.5) 
(Istvan and Deisenhofer, 2000). 
 
(b.) NADP(H) binding 
The NADP(H)–binding site is formed primarily by the S-domain. Among the 
residues with specific interactions with NADP(H), the loop region between helix Sα2 
and strand Sβ2 participates in binding of the NADP(H) ADP moiety. The 
diphosphate is stabilized primarily by main chain interactions with residues located 
in the highly conserved sequence element DAMGXN and by the dipole of helix Sα3 
(Istvan et al., 2000). The binding of NADP(H) causes a conformational change in the 
C-terminus of the enzyme, resulting in complete closure of the active site (Istvan et 
al., 2000).  
 
(c.) HMG binding 
The site of catalysis and active site in HMGR is the 3-hydroxy-3-methylglutaryl 
(HMG) binding pocket. It is located between the L- and S-domain. The residues from 
neighboring monomers contribute to the binding of HMG and the most important 
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structural element in the binding of HMG is the ‘cis-loop’ that bends over the top of 
HMG (Istvan and Deisenhofer, 2000). 
 
1.3.2 Modulation of HMGR activity by phosphorylation 
 The activity of HMGR is controlled through synthesis, degradation and 
phosphorylation to maintain the concentrations of mevalonate-derived products 
(Istvan and Deisenhofer, 2000). In vitro, HMGR may be phosphorylated by several 
protein kinases: AMP-activated protein kinase, protein kinase C and a calmodulin-
dependent protein kinase (Istvan and Deisenhofer, 2000). The AMP-activated protein 
kinase appears to be the major HMGR kinase in liver, which is the site of cholesterol 
synthesis (Istvan and Deisenhofer, 2000). All three kinases phosphorylate serine 872, 
a residue close to the C-terminus of HMGR, and this may reduce the activity of the 
protein (Istvan and Deisenhofer, 2000). 
 
1.3.3 HMGR, mevalonate pathway and cholesterol synthesis 
Cholesterol, an essential component of all animal cell membranes, is derived 
from the uptake of plasma LDL via receptor-mediated endocytosis and de novo 
cellular synthesis (Goldstein and Brown, 1990). By maintaining a balance between 
these external and internal cholesterol sources, the excessive accumulation of 
cholesterol in mammalian cells can be avoided. This balance is achieved through 
feedback regulation on the cholesterol biosynthetic pathway and LDL receptor 
synthesis (Fuhrman et al., 1997). 
Several mechanisms for feedback regulation of LDL receptors and of two 
imperative enzymes involved in cholesterol synthetic pathway ensure the production 
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of sufficient mevalonate for end-products cholesterol. Besides cholesterol synthesis, 
it is essential to regulate mevalonate pathway wisely as it produces non-sterol 
isoprenoids such as dolichols, ubiquinones, steroid hormones, vitamin D, bile acids, 
lipoproteins that are vital for diverse cellular functions, ranging from cell cycle 
progression to cell growth to cell survival (Goldstein and Brown, 1990). In order to 
ensure a constant production of the multiple isoprenoid compounds at all stages of 
growth, cells must precisely regulate mevalonate synthesis to avoid over-
accumulation of potentially toxic products such as cholesterol (Goldstein and Brown, 
1990). Mevalonate homeostasis is achieved through sterol-mediated feedback 
repression of genes for HMGR, HMG-CoA synthase, and LDL receptor as well as 
the post-transcriptional regulation of HMGR by nonsterol isoprenoids (Goldstein and 
Brown, 1990). 
 In mammalian systems, mevalonate is formed from acetyl-CoA and 
acetoacetyl-CoA via the intermediate HMG-CoA (Istvan and Deisenhofer, 2000). 
The four-electron reduction of HMG-CoA to mevalonate, which utilizes two 
molecules of NADPH, is the committed step in the biosynthesis of cholesterol 
(Istvan and Deisenhofer, 2000). This reaction is catalyzed by HMGR. The activity of 
HMGR in mammalian cells is sensitive to accelerate degradation by both sterols and 
non-sterol products of mevalonate pathway (Fuhrman et al., 1997; Goldstein and 
Brown, 1990). HMGR is among the most highly regulated enzymes known 
(Espenshade and Hughes, 2007). Transcription and translation of the HMGR gene 
are low when products of the mevalonate pathway are abundant. Regulation of 
HMGR is also achieved through the decrease in catalytic efficiency of the enzyme by 
phosphorylation of serine 872 by AMP-activated protein kinase (mentioned in 
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Section 1.2.2) and concentration of active protein is regulated by sterol-mediated 
degradation (Espenshade and Hughes, 2007).  
Therefore, this reiterates that regulation of HMGR activity is indeed a 
promising approach in treating hypercholesterolemia individuals due to its vital role 
in cholesterol synthesis.  
 
1.3.4 Effect of natural products on HMGR 
 Some natural products had been discovered to reduce the activity of HMGR, 
like berberine. Berberine is an isoquinoline alkaloid found in barberry and goldenseal 
plants, Oregon grapes, and the traditional Chinese herb golden thread (Wu et al., 
2011). It was found that berberine could interact with the common active sites on 
HMGR. The longer the aliphatic chain on berberine, the stronger its inhibition to 
HMGR activity (Ye et al., 2011). Research showed that hyperhomocysteinemic rats 
treated with berberine for 5 days inhibited HMGR activity and reduced hepatic 
cholesterol content. Such an inhibitory effect was intervened by increased 
phosphorylation of HMGR (Wu et al., 2011). In other words, berberine could inhibit 
hepatic cholesterol biosynthesis via increased phosphorylation of HMGR (Wu et al., 
2011). 
 Some inhibitors, flavonoid conjugates brutieridin and melitidin quantified in 
the bergamot fruit extracts were identified to be structural analogues to simvastatins, 
an HMGR inhibitor (Leopoldini et al., 2010). The geometrical and electronic 
features affecting the binding of these flavonoids to the active site of HMGR and 
their respective inhibition process was researched using computational tool 
(Leopoldini et al., 2010). Besides, four compounds from hawthorn fruit (Crataegus 
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pinnatifida Bge.) like quercetin, hyperoside, rutin and chlorogenic acid were also 
shown to inhibit HMGR, their inhibition to HMGR was enhanced by their weak 
hydrophilic ability (Ye et al., 2010). 
 Phytochemical tocotrienols are farnesylated benzopyran natural products that 
exhibit hypocholesterolemic activity in vitro and in vivo (Pearce et al., 1992). It was 
unveiled that the mechanism of their hypolipidemic action involves post-
transcriptional suppression of HMGR by a process distinct from other known 
inhibitors of cholesterol biosynthesis. γ-Tocotrienol exhibits a 30-fold greater 
activity toward cholesterol biosynthesis inhibition compared to α-tocotrienol in 
HepG2 cells in vitro (Pearce et al., 1992). On the other hand, the synthetic (racemic) 
and natural (chiral) tocotrienols exhibit virtually identical cholesterol biosynthesis 
inhibition as natural tocotrienols and HMGR suppression activities as demonstrated 
in vitro and in vivo (Pearce et al., 1992). 
 Phenolic compound resveratrol was significantly shown to downregulate 
HMGR mRNA expression by real-time PCR analysis (Cho et al., 2008). These 
results indicate that dietary resveratrol reduces serum cholesterol by down-regulating 
hepatic HMGR mRNA expression in hamsters fed a high fat diet (Cho et al., 2008). 
Besides, many extracts or single compounds from Salvia miltiorrhiza, Curcuma 
longa, Coptis chinensis, Rheum undulatum and Panax notoginseng were shown to 
regulate multiple key targets involved in the initiation and propagation of 
atherosclerosis, possibly through the inhibition of HMGR (Zeng et al., 2012).  
 Evidence clearly revealed that certain secondary metabolites derived from 
natural products are potent HMGR inhibitors. Among the tropical plants available in 
Malaysia, the tropical fruit plant that was found fascinating is S. koetjape. Owing to 
